The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3′-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors

Biochemical Pharmacology

Volumn 67, Issue 9, 2004, Pages 1751-1761

  Tramontano, Enzo ^a   Onidi, Loredana ^a   Esposito, Francesca ^a   Badas, Roberta ^a   La Colla, Paolo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

2 (3,4 dihydroxybenzyl) 6 (3,4 dihydroxybenzylidene)cyclohexanone; ATA; Aurintricarboxylic acid; HIV 1; Human Immunodeficiency Virus type 1; L 731,988; Long terminal repeat; LTR; PIC; Preintegration complex; RDS1158; Recombinant integrase; rIN

Indexed keywords

2 (3,4 DIHYDROXYBENZYL) 6 (3,4 DIHYDROXYBENZYLIDENE)CYCLOHEXANONE; 4 [1 (4 FLUOROBENZYL) 4 IODOPYRROL 2 YL] 2,4 DIKETOBUTANOIC ACID; AURINTRICARBOXYLIC ACID; BAICALEIN; CYCLOHEXANONE DERIVATIVE; INTEGRASE INHIBITOR; KETONE DERIVATIVE; L 731 988; MYRICETIN; RDS 1158; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CATALYSIS; CELL CULTURE; CELL FREE SYSTEM; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; KINETICS; OLIGONUCLEOTIDES; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 1842685176     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.01.015     Document Type: Article

References (29)

1. Hindmarsh P., Lei J. Retroviral DNA integration. Microbiol. Mol. Biol. Rev. 63:1999;836-843.
2. Sherman M.P., Greene W.C. Slipping through the door: HIV entry into the nucleus. Microbes Infect. 4:2002;67-73.
3. Andrake M.D., Skalka A.M. Retroviral integrase, putting the pieces together. J. Biol. Chem. 271:1996;19633-19636.
4. Pani A., Marongiu M.E. Anti-HIV-1 integrase drugs: how far from the shelf? Curr. Pharm. Des. 6:2000;569-584.
5. Debyser Z., Cherepanov P., Pluymers W., De Clercq E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol. Biol. 160:2001;139-155.
6. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A.et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 28:2000;646-650.
7. Goldgur Y., Craigie R., Cohen G.H., Fujiwara T., Yoshinaga T., Fujishita T.et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 96:1999;13040-13043.
8. Farnet C.M., Wang B., Lipford J.R., Bushman F.D. Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. U.S.A. 93:1996;9742-9747.
9. Hansen M.S., Smith G.J., Kafri T., Molteni V., Siegel J.S., Bushman F.D. Integration complexes derived from HIV vectors for rapid assays in vitro. Nat. Biotechnol. 17:1999;578-582.
10. Tramontano E., Colla P.L., Cheng Y.C. Biochemical characterization of the HIV-1 integrase 3′-processing activity and its inhibition by phosphorothioate oligonucleotides. Biochemistry. 37:1998;7237-7243.
11. Hazuda DJ, Hastings JC, Wolfe AL, Emini EA. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res 1994;22:1121-2.
12. Wei S.Q., Mizuuchi K., Craigie R. Footprints on the viral DNA ends in Moloney murine leukemia virus preintegration complexes reflect a specific association with integrase. Proc. Natl. Acad. Sci. U.S.A. 95:1998;10535-10540.
13. Brin E., Leis J. Changes in the mechanism of DNA integration in vitro induced by base substitutions in the HIV-1 U5 and U3 terminal sequences. J. Biol. Chem. 277:2002;10938-10948.
14. Brin E., Leis J. HIV-1 integrase interaction with U3 and U5 terminal sequences in vitro defined using substrates with random sequences. J. Biol. Chem. 277:2002;18357-18364.
15. Bushman F.D., Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1339-1343.
16. Sherman P.A., Dickson M.L., Fyfe J.A. Human immunodeficiency virus type 1 integration protein: DNA sequence requirements for cleaving and joining reactions. J. Virol. 66:1992;3593-3601.
17. Cherepanov P., Surratt D., Toelen J., Pluymers W., Griffith J., De Clercq E.et al. Activity of recombinant HIV-1 integrase on mini-HIV DNA. Nucleic Acids Res. 27:1999;2202-2210.
18. Segel IH. Enzyme kinetics. New York: Wiley; 1975. p. 18-80.
19. i. Biochem. J. 129:1972;197-215.
20. Cushman M., Sherman P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochem. Biophys. Res. Commun. 185:1992;85-90.
21. Artico M., Di Santo R., Costi R., Novellino E., Greco G., Massa S.et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation and molecular modeling. J. Med. Chem. 41:1998;3948-3960.
22. Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Invest. Drugs. 10:2001;281-296.
23. Pemberton I.K., Buc H., Buckle M. Displacement of viral DNA termini from stable HIV-1 integrase nucleoprotein complexes induced by secondary DNA-binding interactions. Biochemistry. 37:1998;2682-2690.
24. Ono K., Nakane H., Fukushima M., Chermann J.C., Barre-Sinoussi F. Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. Eur. J. Biochem. 190:1990;469-476.
25. Austin C.A., Patel S., Ono K., Nakane H., Fisher L.M. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J. 282:1992;883-889.
26. LaFemina R.L., Callahan P.L., Cordingley M.G. Substrate specificity of recombinant human immunodeficiency virus integrase protein. J. Virol. 65:1991;5624-5630.
27. Fesen M.R., Pommier Y., Leteurtre F., Hiroguchi S., Yung J., Kohn K.W. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem. Pharmacol. 48:1994;595-608.
28. Inouye Y., Yamaguchi K., Take Y., Nakamura S. Inhibition of avian myeloblastosis virus reverse transcriptase by flavones and isoflavones. J. Antibiot. 42:1989;1523-1525.
29. Mahmood N., Pizza C., Aquino R., De Tommasi N., Piacente S., Colman S.et al. Inhibition of HIV infection by flavanoids. Antiviral Res. 22:1993;189-199.